StockWatch: Positive Phase III Data Sells Investors on Intellia

The data was strong enough for Intellia to continue the rolling Biologics License Application (BLA) submission that it began in April. The company expects to complete the BLA filing by year’s end and hopes to gain FDA approval and launch lonvo-z in the first half of 2027.

The post StockWatch: Positive Phase III Data Sells Investors on Intellia appeared first on GEN - Genetic Engineering and Biotechnology News.